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ABSTRACT
A 58-year-old man was admitted with symptoms of lethargy 
and easy bruising for four months duration. Peripheral blood 
(PB) analysis revealed a white blood cell count (WBC) of 
15.9 × 109/l with monocytes 5.4 × 109/l. Bone marrow (BM) 
was hypercellular with 15% blasts, monocytosis and trilineage 
dysplasia.  Conventional  cytogenetic  analysis  (G-banding) 
detected an apparently normal male karyotype (46,XY). A 
diagnosis of chronic myelomonocytic leukaemia (CMML) 
was made. After 3 years, PB analysis revealed a WBC count 
of 22 × 109/l and a predominance of blasts. BM aspirate 
analysis also revealed 89% myeloid blasts and G-banding 
detected the emergence of an abnormal clone harbouring an 
extra copy of chromosomes 13 and 15. A diagnosis of disease 
transformation to acute myeloid leukaemia (AML) was made. 
Post chemotherapy BM aspirate was very hypocellular and 
the abnormal +13, +15 clone was still present suggesting 
primary refractory disease. A second course of chemotherapy 
was only administered for 24 hours due to complications. 
The abnormal +13,+15 clone was still present and it was 
decided that no further treatment apart from palliative care 
could be offered. The patient died 11 weeks later, five months 
after AML transformation. This is the first description of a 
cytogenetically normal CMML patient transforming to AML 
with the emergence of a unique +13, +15 double trisomy 
resulting in an adverse outcome.
InTRoduCTIon
CMML is a clonal myeloid BM stem cell disorder accounting 
for 10-15% of all myelodysplastic syndromes (MDS)1. The 
specific aetiology of the disease is unknown but exposure 
to  occupational  and  environmental  carcinogens,  ionising 
radiation and cytotoxic agents have all been implicated2. The 
French-American-British (FAB) scheme classified CMML 
as a myelodysplastic syndrome because dysplastic changes 
were  commonly  found  in  both  PB  and  BM3. The  World 
Health Organisation (WHO) classification has now placed 
CMML in a new MDS/MPD category along with juvenile 
myelomonocytic  leukaemia  and  atypical  chronic  myeloid 
leukaemia4. The WHO classification has also recommended 
that  PB  and  BM  blast  counts  (includes  myeloblasts, 
monoblasts and promonocytes) be used to distinguish between 
CMML-I (<5% in PB or <10% in BM) and CMML-II (5-19% 
in PB or 10-19% in BM) sub-types4,5. 
Prognosis  is  extremely  variable  in  CMML.  The  median 
survival  time  is  in  the  order  of  12  to  24  months  with 
transformation  to  AML  occurring  in  about  15-20%  of 
patients6,7.  In  the  majority  of  prognostic  studies  carried 
out, the percentage of blasts in PB and BM appears to be 
the most important factor in determining survival6,8. Other 
factors contributing to survival of CMML patients include 
clonal chromosome abnormalities, WBC, circulating levels of 
haemoglobin, platelets, marrow erythroid cells, serum lactate 
dehydrogenase and β2-microglobulin6,7. Clonal chromosome 
abnormalities are found in 20-40% of patients but none are 
classified as being disease-specific6. 
In the present case, G-banding and interphase FISH techniques 
were used to monitor the karyotype status of a patient who 
transformed to AML after a 3 year history of cytogenetically 
normal CMML. Upon transformation the patient acquired a 
unique double trisomy for chromosomes 13 and 15 and had 
a poor outcome. 
MeThodS
Case description
A 58-year-old man was admitted to hospital in March 1999 
presenting with symptoms of lethargy and easy bruising for 
approximately  four  months  duration.  On  examination  no 
abnormality was detected. PB analysis revealed haemoglobin 
13.2g/dl, WBC  15.9  ×  109/l  with  monocytes  5.4  ×  109/l, 
neutrophils 6.7 × 109/l, neutrophil band forms 0.6 × 109/l, 
lymphocytes 3.2 × 109/l and platelets 48.0 × 109/l. BM was 
markedly hypercellular with 15% blasts, monocytosis and 
trilineage dysplasia. G-banding and interphase FISH analyses 
of  his  BM  aspirate  demonstrated  an  apparently  normal 
male karyotype. In particular there was no evidence of a © The Ulster Medical Society, 2007.
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Philadelphia chromosome by G-banding or a BCR/ABL gene 
rearrangement by interphase FISH. A diagnosis of CMML 
was made.
In February 2002 he became progressively anaemic with a 
rising WBC and progressive splenomegaly. PB examination 
confirmed  the  increase  in  his  WBC  to  be  secondary  to 
transformation to AML. On admission to hospital PB analysis 
revealed haemoglobin 8.7g/dl, WBC 22 × 109/l (predominantly 
blasts) and platelets 6.0 × 109/l. BM aspirate analysis revealed 
89%  myeloid  blasts  with  CD7,  CD13,  CD33,  CD34  and 
CD117 positivity. G-banding and interphase FISH analyses 
detected an abnormal clonal cell population harbouring an 
extra copy of chromosomes 13 and 15. A diagnosis of disease 
transformation to AML (M2 FAB-type) was made.
He  was  treated  with  intensive  chemotherapy.  Soon  after 
commencement he became ill with septic shock but eventually 
recovered to complete his 10-day course of chemotherapy. He 
remained pancytopenic. His 35 day post chemotherapy BM 
aspirate was very hypocellular and still showed evidence of 
the abnormal +13,+15 clone suggesting primary refractory 
disease. A second course of chemotherapy was planned but 
after the first day of Fludarabine treatment he developed septic 
shock, became hypotensive and required inotropic support. 
Chemotherapy was therefore abandoned and he made some 
recovery but remained in a very poor state and was not fit to 
complete the course of chemotherapy. The patient remained 
pancytopenic with no recovery of his blood counts. G-banding 
and interphase FISH analyses still confirmed the presence of 
the abnormal +13,+15 clone. No further treatment apart from 
palliative care could be offered. The patient died 11 weeks 
later, five months after transforming to AML.
Conventional Cytogenetics (G-banding) and Interphase FISH 
i(FISH)
Chromosome spreads and interphase nuclei were examined 
from 24-hour unstimulated BM cells at CMML diagnosis, 
transformation to AML and after each course of chemotherapy 
using  G-banding  and  i(FISH)  techniques  respectively. 
Chromosomes were Giemsa-Trypsin-Giemsa (GTG) banded 
and karyotypes were described according to ISCN 20059. 
i(FISH) analyses were carried out using a BCR/ABL dual 
fusion  probe  (at  diagnosis  only)  to  screen  for  a  t(9;22) 
rearrangement and chromosome 13, 15 and Y enumeration 
probes  to  assess  ploidy  status  at  CMML  diagnosis 
(retrospectively),  transformation  to  AML  and  after  each 
course of chemotherapy according to the protocols provided 
by the manufacturer (Abbott Vysis, UK). Y chromosome 
ploidy status was monitored because of the apparent age-
related link between trisomy 15 (+15) and Y chromosome 
loss (-Y), a phenomenon that has previously been reported 
in the literature10. 
ReSulTS
i(FISH) analysis detected a normal Y chromosome ploidy 
level at CMML diagnosis, AML transformation and after each 
course of chemotherapy. There was therefore no evidence of 
Y chromosome loss during the course of the disease.
CMMl diagnosis (March 1999)
G-banded  analysis  detected  an  apparently  normal  male 
karyotype with no evidence of a Philadelphia chromosome 
(Fig.  1A).  i(FISH)  analysis  did  not  detect  an  underlying 
t(9;22) translocation or aneuploidies involving chromosomes 
13 and/or 15 (Fig 1A).
AMl transformation (March 2002)
G-banded analysis detected 3 copies of chromosomes 13 and 
15 in 5 out of 7 cells analysed (Fig 1B). i(FISH) analysis using 
a cytospin preparation detected 3 copies of chromosomes 
13 and 15 in 79 out of 100 nuclei examined. These results 
demonstrate the emergence of an abnormal clone harbouring 
an extra copy of chromosomes 13 and 15.
Post Chemotherapy (Course 1)
G-banded  analysis  detected  3  copies  of  chromosomes 
13 and 15 in 9 out of 30 cells analysed. i(FISH) analysis 
detected 3 copies of chromosomes 13 and 15 in 9 out of 100 
nuclei examined. There was therefore evidence of the same 
aneuploidy involving chromosomes 13 and 15 detected at 
AML transformation.
Post Chemotherapy (Course 2)
fig 1. Conventional cytogenetic analysis using G-banded 
metaphase spreads and interphase FISH analysis from 
A) unstimulated bone marrow cell suspensions at CMML 
diagnosis (March 1999) and B) unstimulated bone marrow cell 
suspensions (conventional cytogenetic analysis only) and a 
cytospin preparation (interphase FISH only) at transformation 
to AML (March 2002). Chromosome 13 is highlighted (green) 
and chromosome 15 (red). 46,XY karyotype indicated in (A). 
48,XY,+13,+15 karyotype indicated in (B).© The Ulster Medical Society, 2007.
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Chemotherapy  was  abandoned  after  24  hours  due  to 
complications.  G-banded  analysis  detected  3  copies  of 
chromosomes  13  and  15  in  all  5  cells  analysed.  i(FISH) 
analysis detected 3 copies of chromosomes 13 and 15 in 18 
out of 100 nuclei examined. There was therefore still evidence 
of the aneuploidy involving chromosomes 13 and 15 (table 
I).
dISCuSSIon
We report a male patient having had a three year history of 
cytogenetically normal CMML before transforming to AML. 
Disease transformation coincided with the emergence of a 
unique +13,+15 double trisomy in a proportion of the cells 
suggesting further evolution of the malignant stem cells. The 
WHO classification uses the following criteria to make a 
diagnosis of CMML11: 
Persistent PB monocytosis (> 1 x109/L), 
No Philadelphia chromosome or BCR/ABL fusion gene, 
<  20%  blasts  (includes  myeloblasts,  monoblasts  and 
promonocytes) in PB or BM,
Dysplasia in one or more myeloid lineages. 
Furthermore, if myelodysplasia is absent or minimal, CMML 
can still be diagnosed if the criteria mentioned above are met 
and an acquired chromosome abnormality is detected in the 
BM or monocytosis has been persistent for at least 3 months 
and all other causes of monocytosis have been excluded11. Our 
patient met all of the above criteria having a monocyte count 
of 5.4 x 109/l, no Philadelphia chromosome or BCR/ABL 
gene rearrangement, 15% blasts in the BM and trilineage 
dysplasia. 
The number of blasts usually account for <5% of WBC in 
PB and <10% of the nucleated marrow cell at the time of 
diagnosis. A higher blast count can identify patients who may 
be at risk of having a poor prognosis or who may undergo 
rapid transformation to an acute leukemia8,12,13. Interestingly, 
our patient, according to the WHO classification4,5, had a 
CMML-II  sub-type  (i.e.  15%  BM  blasts)  with  an  overall 
survival (~40 months) that was not only better than the 12 to 
24 months median survival time reported in the literature6,7 
but also transformed to AML 36 months after initial disease 
diagnosis.
Clonal  chromosome  abnormalities  are  found  in  20-40% 
of  CMML  cases  but  none  have  been  classified  as  being 
disease-specific6. The most frequent recurring chromosome 
abnormalities  include  trisomy  8,  monosomy  7,  deletions 
of  part  of  the  long  arm  of  chromosome  7,  structural 
abnormalities of the short arm of chromosome 12 and complex 
karyotypes.  CMML  patients  with  a  clonal  chromosome 
abnormality usually have a shorter survival time compared 
to  cytogenetically  normal  CMML  patients6.  Furthermore, 
it has not yet been possible to stratify the recurring clonal 
chromosome abnormalities into any particular risk category. 
However, a rare t(5;12)(q33;p13) chromosome translocation 
found in 1-2% of CMML patients has been associated with 
a number of chronic MPD/MDS disorders, often categorised 
as eosinophilic leukaemia or as CMML with eosinophilia14,15. 
The molecular mechanism of leukaemogenesis is fusion of the 
Platelet-Derived Growth Factor Receptor-β (PDGFRβ) gene 
at 5q33 with the ETV6 (previously known as TEL) gene at 
12p1314,16. The identification of patients with this PDGFRβ 
gene  rearrangement  is  of  major  prognostic  importance, 
not because of any particular impact on the natural course 
of  CMML,  but  in  view  of  their  reported  responsiveness 
to  treatment  with  the  tyrosine  kinase  inhibitor  imatinib 
mesylate17,18.
The  association  of  trisomy  of  various  chromosomes  with 
haematological  malignancies  is  well  established19.  The 
presence  of  some  single  acquired  autosomal  trisomies  is 
also supportive of diagnosis and indicative of prognosis in 
haematological  disorders.  Single  autosomal  trisomies  for 
chromosomes 13 and 15 are very rare in AML20. Trisomy 13 
as the sole cytogenetic abnormality is found in less than 1% of 
AML cases and to the best of our knowledge there have been 
only 70 cases reported in the literature20. Patients are usually 
elderly males presenting with M0 or M1 AML and having 
a generally poor response to treatment21. These patients not 
only have a low rate of complete remission22 but also remain 
in complete remission for a short period of time23,24. The 
molecular mechanism whereby trisomy 13 confers neoplastic 
potential on a clone is not understood but candidate genes 
include the FMS-like tyrosine kinase (FLT) proto-oncogene 
(mapped to 13q12) and the retinoblastoma gene (mapped to 
13q14). 
Trisomy 15 as the sole autosomal abnormality is also very 
rare in leukaemia being found in both myeloid and lymphoid 
leukaemias25,26. To the best of our knowledge there have been 
only 11 cases of trisomy 15 as the sole autosomal trisomy in 
AML reported in the literature20. The significance of trisomy 
15 in haematological neoplasia and the molecular mechanism 
whereby trisomy 15 confers neoplastic potential on a clone 
is again not understood. To date there are no known genes/
proteins  associated  with  trisomy  15  and  haematological 
malignancy25.  However,  disruption  of  candidate  genes  on 
chromosome 15 known to contribute to transformation of 
myeloid cells include the PML gene (mapped to 15q22) in 
acute promyelocytic leukaemia (M3 AML)27 and the AF15q14 
Ta b l e  I. 
The number of cells detected with 3 copies of chromosomes 
13 and 15 using conventional cytogenetics (G-banding) 
and interphase FISH techniques (expressed as the number 
detected out of the total number of cells analysed). 
STAGE OF DISEASE
Number of cells with 3 





(March 1999) 0/10 0/100
AML transformation 
(March 2002) 5/7 79/100
Post Course 1 Chemotherapy 9/30 9/100
Post Course 2 Chemotherapy 5/5 18/100© The Ulster Medical Society, 2007.
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gene (mapped to 15q14) fused to the MLL gene (mapped to 
11q23) in AML with a t(11;15)(q23;q14) translocation28.
Although the presence of a clonal chromosome abnormality 
in BM is usually indicative of haematological malignancy, 
not  all  apparent  chromosome  abnormalities  can  be  taken 
as proof of malignancy. Loss of the Y chromosome in BM 
of elderly males has been accepted as being an age-related 
phenomenon29.  There  is  also  evidence  in  the  literature 
suggesting that individual trisomies for chromosomes such as 
7 and 15 may not be malignant10,30. An apparent link involving 
trisomy 15 and loss of the Y chromosome in relation to an 
age-related phenomenon has even been suggested10. Trisomy 
15 has also been observed as a minor clone in patients with 
anaemia,  MDS  and  Non-Hodgkin’s  Lymphoma  (NHL) 
but as a major clone in patients with AML31. Although the 
significance of trisomy 15 as a single autosomal abnormality 
remains unclear, it may, like loss of the Y chromosome, be 
unhelpful as a marker of malignancy. 
i(FISH) analysis was therefore carried out on all samples 
received for cytogenetic investigation using a chromosome 
Y  enumeration  probe  in  conjunction  with  the  13  and  15 
chromosome enumeration probes in order to investigate this 
‘age-related association’ involving chromosomes 15 and Y. 
i(FISH) analysis did not detect Y chromosome loss in any 
of the samples examined. This immediately indicates there 
was  no  age–related Y  chromosome  loss. This  result  also 
demonstrates the lack of an apparent age-related link between 
chromosome 15 and Y since the extra copy of chromosome 
15 was only ever found in the presence of an extra copy of 
chromosome 13 in the samples analysed from the time of 
disease transformation to AML. This would therefore suggest 
that the extra copy of chromosomes 13 and 15 may both play 
a role in the malignant transformation to AML.
The  case  presented  here  is  therefore  notable  for  the 
emergence of a novel +13, +15 double trisomy cell population 
in  a  patient  with  AML  having  had  a  3  year  history  of 
cytogenetically normal CMML. Both trisomy 13 and trisomy 
15 as sole autosomal trisomies are known to be very rare 
in  haematological  disorders.  This  case  demonstrates  that 
the coexistence of a +13,+15 double trisomy is not only an 
extremely rare phenomenon but also may have contributed to 
a particularly poor outcome in this patient.
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